Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.

Sponsor: Zeneus Pharma
Study ID: NCT00244127
Phase: PHASE2
Status: Unknown

Conditions

Aggressive Non-Hodgkin's Lymphoma in the Elderly.

Eligibility Criteria

Sex: ALL
Age: 65 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Cyclophosphamide, oncovin, myocet, prednisone & rituximab (R-COMP) — DRUG

Study Details

To evaluate the safety and efficacy of R-COMP in elderly patients with advanced aggressive NHL. Myocet (non-pegylated liposomal doxorubicin) replaces conventional doxorubicin in the R-CHOP regimen.

Key Dates

Start date: Oct 31, 2002
Status verified: Oct 2005

Study Design

Enrollment: 75 participants
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Primary Outcome Measure

Response rate